What is the future of ocular lubricants in dry eye treatment?

8 May 2019
Spring 2019

Léa Surugue looks at the dynamic expansion of next-generation artificial tears, and asks what other tailored products are emerging.

The TFOS DEWS II report of 2017 established the idea that dry eye disease (DED) is a multifactorial disorder. Manifesting itself with varying degrees of severity, DED requires a variety of treatment approaches. Research has been moving along quickly to discover new products that can best address this complexity, while recognising the difficulty of finding a universal treatment for all. 

Until now, traditional ocular lubricants have tended to offer patients only a palliative approach to dry eye symptom management, without necessarily trying to resolve the causes of the disorder. 

Jennifer Craig FCOptom, Vice-Chair and one of the lead authors of the TFOS DEWS II report, explains: “New lubricants are working harder than ever to address the different reasons people have dry eyes, which often requires complex combinations of features within the drops. 

Sign in to continue

Forgotten password?
Register

Not already a member of The College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

From today, optometrists in the whole of the UK will return to the Green phase as we stand down the Amber phase COVID-19 guidance.

The College is asking for feedback from members on changes to its patient leaflets.

We have responded to the Hewitt review: call for evidence on ICSs in England, to help inform a new way of working.